Helping an oral diabetes drug go the extra mile

November 14, 2018

Stephen Buckley and colleagues have reformulated a prospective therapy for type 2 diabetes (T2D) now under clinical investigation as an oral treatment. Their modifications allowed the therapy to be effectively absorbed in the stomach - potentially offering patients a less invasive route of administration compared to the currently approved version of the therapy, which can only be dispensed by injection. Their research potentially expands the use of a T2D therapy that is now undergoing phase 3 clinical trials as an oral treatment. T2D affects over 30 million Americans, and one of the most successful T2D therapies involves a peptide hormone named GLP-1, which stimulates the release of insulin and maintains healthy blood sugar levels. Researchers have derived analogs of GLP-1 such as semaglutide that can lower blood sugar levels and blood pressure in T2D patients, but these peptides quickly break down in the gastrointestinal tract before they can be absorbed, limiting their route of administration to an injection. In an effort to offer clinicians greater treatment flexibility and improve T2D patient adherence to treatment programs, Buckley et al. created an oral formulation of semaglutide that was more readily absorbed. They designed and developed a tablet that contains both semaglutide and a fatty acid derivative named SNAC, which protected the semaglutide from being degraded by digestive enzymes. The authors then administered their tablet to dogs and humans and found it was absorbed by epithelial cells in the stomach rather than in the intestines, unlike most other drugs. The authors say that incorporating SNAC and similar compounds into oral peptide therapies could further boost their therapeutic potential.

American Association for the Advancement of Science

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to